Free Trial

Medifast (MED) Competitors

Medifast logo
$12.70 -0.27 (-2.04%)
As of 12:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MED vs. LW, NOMD, HNST, PRE, and USNA

Should you buy Medifast stock or one of its competitors? Medifast's main competitors and comparable companies include Lamb Weston (LW), Nomad Foods (NOMD), Honest (HNST), Prenetics Global (PRE), and USANA Health Sciences (USNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "consumer staples" sector.

How does Medifast compare to Lamb Weston?

Lamb Weston (NYSE:LW) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Lamb Weston had 2 more articles in the media than Medifast. MarketBeat recorded 5 mentions for Lamb Weston and 3 mentions for Medifast. Lamb Weston's average media sentiment score of 0.63 beat Medifast's score of -0.47 indicating that Lamb Weston is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lamb Weston
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medifast
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lamb Weston has a net margin of 3.85% compared to Medifast's net margin of -13.64%. Lamb Weston's return on equity of 23.27% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Lamb Weston3.85% 23.27% 5.70%
Medifast -13.64%-6.90%-5.34%

Lamb Weston presently has a consensus price target of $53.82, indicating a potential downside of 4.13%. Medifast has a consensus price target of $12.00, indicating a potential downside of 7.15%. Given Lamb Weston's stronger consensus rating and higher possible upside, research analysts clearly believe Lamb Weston is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lamb Weston
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.36
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

89.6% of Lamb Weston shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 1.0% of Lamb Weston shares are held by insiders. Comparatively, 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lamb Weston has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Medifast has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lamb Weston$6.61B1.17$290M$1.8330.67
Medifast$385.79M0.37-$18.67M-$3.69N/A

Summary

Lamb Weston beats Medifast on 14 of the 17 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Medifast (NYSE:MED) and Nomad Foods (NYSE:NOMD) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

95.5% of Medifast shares are owned by institutional investors. Comparatively, 75.3% of Nomad Foods shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Medifast currently has a consensus target price of $12.00, indicating a potential downside of 7.15%. Nomad Foods has a consensus target price of $13.80, indicating a potential upside of 15.53%. Given Nomad Foods' stronger consensus rating and higher probable upside, analysts clearly believe Nomad Foods is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Nomad Foods
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Medifast has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Nomad Foods has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$385.79M0.37-$18.67M-$3.69N/A
Nomad Foods$3.43B0.49$154.66M$1.1010.86

In the previous week, Nomad Foods had 1 more articles in the media than Medifast. MarketBeat recorded 4 mentions for Nomad Foods and 3 mentions for Medifast. Nomad Foods' average media sentiment score of 1.12 beat Medifast's score of -0.47 indicating that Nomad Foods is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medifast
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nomad Foods
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nomad Foods has a net margin of 4.46% compared to Medifast's net margin of -13.64%. Nomad Foods' return on equity of 8.63% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-13.64% -6.90% -5.34%
Nomad Foods 4.46%8.63%3.42%

Summary

Nomad Foods beats Medifast on 14 of the 16 factors compared between the two stocks.

How does Medifast compare to Honest?

Honest (NASDAQ:HNST) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Honest has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, Medifast has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Honest has higher earnings, but lower revenue than Medifast. Medifast is trading at a lower price-to-earnings ratio than Honest, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Honest$371.32M1.47-$15.69M$0.697.26
Medifast$385.79M0.37-$18.67M-$3.69N/A

45.5% of Honest shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 9.4% of Honest shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Honest had 7 more articles in the media than Medifast. MarketBeat recorded 10 mentions for Honest and 3 mentions for Medifast. Honest's average media sentiment score of 0.73 beat Medifast's score of -0.47 indicating that Honest is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Honest
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Medifast
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Honest has a net margin of 23.47% compared to Medifast's net margin of -13.64%. Honest's return on equity of 5.10% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Honest23.47% 5.10% 4.03%
Medifast -13.64%-6.90%-5.34%

Honest presently has a consensus price target of $5.43, suggesting a potential upside of 8.28%. Medifast has a consensus price target of $12.00, suggesting a potential downside of 7.15%. Given Honest's stronger consensus rating and higher probable upside, equities analysts plainly believe Honest is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Honest
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.44
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Honest beats Medifast on 15 of the 17 factors compared between the two stocks.

How does Medifast compare to Prenetics Global?

Medifast (NYSE:MED) and Prenetics Global (NASDAQ:PRE) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Medifast presently has a consensus target price of $12.00, suggesting a potential downside of 7.15%. Prenetics Global has a consensus target price of $37.17, suggesting a potential upside of 125.12%. Given Prenetics Global's stronger consensus rating and higher possible upside, analysts plainly believe Prenetics Global is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Prenetics Global
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Medifast has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

In the previous week, Medifast had 2 more articles in the media than Prenetics Global. MarketBeat recorded 3 mentions for Medifast and 1 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 1.82 beat Medifast's score of -0.47 indicating that Prenetics Global is being referred to more favorably in the news media.

Company Overall Sentiment
Medifast Neutral
Prenetics Global Very Positive

Medifast has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$385.79M0.37-$18.67M-$3.69N/A
Prenetics Global$92.39M3.01-$37.71M-$4.16N/A

Medifast has a net margin of -13.64% compared to Prenetics Global's net margin of -47.43%. Medifast's return on equity of -6.90% beat Prenetics Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-13.64% -6.90% -5.34%
Prenetics Global -47.43%-21.41%-15.56%

95.5% of Medifast shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Medifast beats Prenetics Global on 11 of the 17 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

Medifast (NYSE:MED) and USANA Health Sciences (NYSE:USNA) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

USANA Health Sciences has higher revenue and earnings than Medifast. USANA Health Sciences is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$385.79M0.37-$18.67M-$3.69N/A
USANA Health Sciences$913.36M0.27$10.76M-$1.15N/A

Medifast currently has a consensus target price of $12.00, indicating a potential downside of 7.15%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than USANA Health Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
USANA Health Sciences
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Medifast has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, USANA Health Sciences had 4 more articles in the media than Medifast. MarketBeat recorded 7 mentions for USANA Health Sciences and 3 mentions for Medifast. USANA Health Sciences' average media sentiment score of 0.17 beat Medifast's score of -0.47 indicating that USANA Health Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medifast
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
USANA Health Sciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.5% of Medifast shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 0.8% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

USANA Health Sciences has a net margin of -2.34% compared to Medifast's net margin of -13.64%. USANA Health Sciences' return on equity of 3.56% beat Medifast's return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-13.64% -6.90% -5.34%
USANA Health Sciences -2.34%3.56%2.62%

Summary

USANA Health Sciences beats Medifast on 9 of the 15 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MED vs. The Competition

MetricMedifastPersonal Care Products IndustryConsumer Staples SectorNYSE Exchange
Market Cap$142.00M$27.12B$17.61B$23.30B
Dividend YieldN/A6.05%3.21%3.78%
P/E Ratio-3.4429.7825.8629.57
Price / Sales0.472.141.733.18
Price / Cash31.2518.1415.7315.64
Price / Book0.703.253.634.06
Net Income-$18.67M$1.19B$844.63M$1.08B
7 Day Performance-4.82%-3.58%-0.45%-2.68%
1 Month Performance6.85%-4.07%0.69%-0.79%
1 Year Performance11.69%-12.68%-2.22%6.04%

Medifast Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MED
Medifast
1.3735 of 5 stars
$12.71
-2.0%
$12.00
-5.5%
+13.6%$142.00M$299.57MN/A380
LW
Lamb Weston
2.2457 of 5 stars
$55.25
+0.3%
$53.82
-2.6%
-1.5%$7.61B$6.62B30.1910,000
NOMD
Nomad Foods
4.9768 of 5 stars
$11.76
-2.2%
$13.80
+17.4%
-2.2%$1.64B$2.98B10.697,752
HNST
Honest
3.5813 of 5 stars
$4.67
+5.2%
$5.43
+16.2%
+94.2%$514.07M$371.32M6.77174
PRE
Prenetics Global
4.5403 of 5 stars
$15.94
-1.1%
$37.17
+133.2%
+35.3%$268.97M$92.39MN/A98

Related Companies and Tools


This page (NYSE:MED) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners